2-(4-morpholinyl)-4H-1-benzopyran-4-one: an aminochromone; exhibits both antiproliferative and antichemotactic activity in vitro
ID Source | ID |
---|---|
PubMed CID | 131255 |
CHEMBL ID | 367315 |
SCHEMBL ID | 3361567 |
MeSH ID | M0217347 |
Synonym |
---|
130735-56-7 |
4h-1-benzopyran-4-one, 2-(4-morpholinyl)- |
u 67154 |
2-(4-morpholinyl)-4h-1-benzopyran-4-one |
u-67154 |
u67154 |
2-morpholino-4h-chromen-4-one |
2-morpholin-4-yl-chromen-4-one |
bdbm50098118 |
ly-292223 |
CHEMBL367315 , |
SCHEMBL3361567 |
2-(4-morpholinyl)-4h-benzopyran-4-one |
QNFWERYZJLBANZ-UHFFFAOYSA-N |
2-morpholinochromone |
DTXSID30156701 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Neprilysin | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0002 | 0.5422 | 6.7000 | AID240943 |
Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.0000 | 0.0003 | 0.3095 | 2.3000 | AID484153 |
Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.0000 | 0.0003 | 0.3209 | 2.3000 | AID484153 |
Angiotensin-converting enzyme | Homo sapiens (human) | IC50 (µMol) | 13.4000 | 0.0001 | 0.5336 | 10.0000 | AID241822 |
Endothelin-converting enzyme 1 | Homo sapiens (human) | IC50 (µMol) | 0.0395 | 0.0120 | 0.5678 | 2.0000 | AID241703; AID241738 |
DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | IC50 (µMol) | 4.2150 | 0.0005 | 1.3500 | 10.0000 | AID241691; AID241922; AID484153; AID53308 |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 10.0000 | 0.0002 | 0.6603 | 10.0000 | AID484153 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Heat shock protein HSP 90-alpha | Homo sapiens (human) | EC50 (µMol) | 50.0000 | 0.0040 | 0.1331 | 1.2000 | AID87633 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID241738 | Inhibitory concentration against human ECE-1 expressed in MDCK cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. |
AID240943 | Inhibitory concentration against Neprilysin | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. |
AID87633 | Competitive binding towards Heat shock protein HSP 90-alpha | 2001 | Bioorganic & medicinal chemistry letters, Apr-09, Volume: 11, Issue:7 | LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. |
AID248376 | Inhibitory concentration against DNA synthesis in LNZ308 glioblastoma cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. |
AID241691 | Inhibition of DNA dependent protein kinase isolated from HeLa cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. |
AID484153 | Inhibition of DNA-dependent protein kinase | 2010 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12 | Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors. |
AID248327 | Inhibitory concentration againstDNA synthesis in LN18 glioblastoma cells | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. |
AID155500 | Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells | 2001 | Bioorganic & medicinal chemistry letters, Apr-09, Volume: 11, Issue:7 | LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. |
AID241922 | Inhibitory activity against DNA-dependent protein kinase (DNA-PK) at 0.5 uM | 2004 | Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 | Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. |
AID241822 | Inhibitory concentration against human angiotensin I converting enzyme | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. |
AID53308 | Inhibition of DNA dependent protein kinase activity without hsp90 alpha protein | 2001 | Bioorganic & medicinal chemistry letters, Apr-09, Volume: 11, Issue:7 | LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. |
AID241703 | Inhibitory concentration against human ECE-1 by RIA | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |